What did Citi change in its GSK analyst rating on Feb 09, 2026?

Citi maintained a **Neutral** rating and raised the price target to **2,250 GBp** from **1,900 GBp** on Feb 09, 2026. The action signals a higher valuation estimate with no upgrade to a buy recommendation.

How should investors interpret the GSK price target increase?

A higher price target suggests Citi expects stronger near‑term results or valuation support. It offers modest upside but does not change the Neutral stance, so investors should not treat it as a buy signal alone.

Does the GSK analyst rating change alter Meyka’s view?

Meyka AI still rates GSK **B+**. The Citi update modestly supports valuation but does not shift Meyka’s assessment of fundamentals or consensus materially.

Where can I read the full Citi note on the GSK analyst rating?

The Citi price target update appears in the market report covered by TheFly. For U.S. quotes and broader context, check the MarketWatch GSK quote and summary pages.

Analyst Ratings

Citi Maintains Neutral on GSK (GSK plc) Feb 09, 2026; PT 2,250 GBp

ByDanny Kontos February 10, 2026February 10, 2026

Citigroup maintained a Neutral rating on GSK plc (GSK) on Feb 09, 2026 while lifting its price target to 2,250 GBp from 1,900 GBp. This GSK analyst rating keeps Citi’s stance steady but signals a modest bump in valuation expectations. Investors should note the maintained Neutral voice and the increased price target as the key takeaway. Meyka AI’s real-time coverage flagged the update for context and market reaction.